期刊文献+

HPLC测定盐酸美金刚片的含量和溶出度 被引量:1

Determination of content and dissolution of Memantine hydrochloride tablet by HPLC
原文传递
导出
摘要 目的采用邻苯二甲醛柱前衍生HPLC法测定盐酸美金刚片的含量和溶出度。方法样品与邻苯二甲醛衍生试剂在室温下反应3 min后,进样测定,采用Phenomenex C18色谱柱(250 mm×4.6 mm,5μm),流动相为0.05 mol·L^-1乙酸钠(冰乙酸调p H6)-甲醇(5∶95),流速1 mL·min^-1,检测波长338 nm。结果方法的线性范围为1-200μg·mL^-1(r=0.9998),RSD=1.9%(n=6);平均回收率为98.5%-100.1%;在室温条件下,衍生产物在20 min内稳定。结论所用方法简单快速、专属性好、结果准确可靠,可用于盐酸美金刚片剂的含量测定及溶出度的研究。 OBJECTIVE To establish a method for the determination of content and dissolution of Memantine hydrochloride( MH)tablet by o- phthalaldehyde pre- column derivatization HPLC. METHODS The derivatization reaction was carried out with o-phthalaldehyde for 3 min at room temperature. Then the derivatization was separated on a Phenomenex C18( 250 mm × 4. 6 mm,5 μm)column with the flow rate of 1. 0 mL·min^- 1and the detection wavelength of 338 nm. Mobile phase consisted of 0. 05 mol·L^- 1sodium acetate( p H6)- methanol( 5∶95). RESULTS Excellent linear correlation was showed within the range of 1- 200 μg·m L- 1( r =0. 9998). The RSD was 1. 9%( n = 6) and the average recovery was 98. 5%- 100. 1%. The derivatization was stable within 20 min.CONCLUSION The method is rapid,specificity,and accurate. It can be applied for content and dissolution determination of MH tablets.
出处 《华西药学杂志》 CAS CSCD 2016年第1期100-102,共3页 West China Journal of Pharmaceutical Sciences
关键词 邻苯二甲醛柱前衍生 高效液相色谱法 盐酸美金刚 含量测定 溶出度 质量控制 o-Phthalaldehyde pre-column derivatization HPLC Memantine hydrochloride Determination Dissolution Quality control
  • 相关文献

参考文献7

二级参考文献80

  • 1于泓,牟世芬.氨基酸分析方法的研究进展[J].分析化学,2005,33(3):398-404. 被引量:135
  • 2中岛宪一郎.荧光标记试剂[J].化学工程师,1995(6):38-42. 被引量:1
  • 3Schneider LS, Dagerman KS, Higgins JP, et al. Lack of evi-dence for the efficacy of memantine in mild Alzheimer disease [J]. Arch Neuro1,2011,68 ( 8 ) :991-998.
  • 4Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease[J]. J Neurol Neurosurg Psychiatry, 2009,80(6) :600-607.
  • 5Pomara N, Ott BR, Peskind E, et al. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial [J]. Alzheimer Dis Assoc Disord ,2007,21 ( 1 ) :60-64.
  • 6Sicras-Mainar A, Vergara J, Leon-Colombo T, et al. Retrospective comparative analysis of anfidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine [J]. Rev Neuro1,2006,43 ( 8 ) :449-453.
  • 7Riordan KC, Hoffman Snyder CR, Wellik KE, et al. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic [J]. Neurologist, 2011,17 ( 2 ) : 121-123.
  • 8Almeida AA, Camposa DR, Bernasconi G, et al. Determination of memantine in human plasma by liquid chromatographyelectrospray tandem mass spectrometry:application to a bioequivalence study [J]. Journal of Chromatography B, 2007, 848(2) :311-316.
  • 9Ming-Yan Liu, Sheng-Nan Meng, Hui-Zhe Wu, et al. Phannacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry [J]. Clinical Therapeutics,2008,30 (4) :641-653.
  • 10Schmitt FA,Van Dyck CH, Wichems CH, et al. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil:an exploratory reanalysis [J]. Alzheimer Dis Assoc Disord, 2006,20 ( 4 ) : 255-262.

共引文献105

同被引文献10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部